Calidi Biotherapeutics, Inc.

Calidi is based in the United States, where its principal executive and administrative offices and laboratory facility are located in San Diego. The company also operates through wholly owned subsidiaries in Germany and Australia, reflecting a development footprint that extends beyond the U.S. for research, staffing, and clinical trial execution. Management specifically noted foreign vendors and employees in Europe, particularly Germany, and a subsidiary in Australia formed to support a portion of planned clinical trial activities for the SNV1 program. Because the company is still pre-commercial, geography matters mainly through where R&D work is performed, where trial activity is conducted, and where foreign-currency costs are incurred.

Calidi faces substantial going-concern and financing risk because it has no product revenue and expects continuing operating losses as it funds research, trials, and regulatory work. Clinical-stage biotechnology companies also face high technical and regulatory risk: product candidates may fail in preclinical testing, clinical trials, or regulatory review, which would reduce or eliminate future value. The company is exposed to manufacturing and supply-chain risk because it depends on third-party vendors for clinical drug product and supply, and those arrangements can be costly or disrupted. It also has foreign operating exposure through Germany and Australia, which introduces currency, staffing, and cross-border execution risk, while broader market conditions can affect its ability to raise capital on acceptable terms.